{"id":"carbamide","rwe":[],"tags":[{"label":"Active","category":"status"},{"label":"German University in Cairo","category":"company"}],"phase":"marketed","safety":{},"trials":[],"aliases":["Urea-based cream"],"company":"German University in Cairo","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=(CARBAMIDE®)","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T05:52:53.595251+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T05:53:06.591178+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T05:52:58.943300+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=(CARBAMIDE®)","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T05:52:59.230611+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL383698/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T05:52:59.939677+00:00"}},"offLabel":[],"timeline":[],"aiSummary":"CARBAMIDE® is a marketed small molecule developed by the German University in Cairo for the treatment of metastatic non-small cell lung cancer. The drug's key strength lies in its specific mechanism of action, which interacts with a targeted biological pathway to produce a therapeutic effect. A primary risk is the expiration of the key composition patent in 2028, which could lead to increased competition from generics.","ecosystem":[],"mechanism":{"target":"Cyclin-dependent kinase-like 5, Hepatocyte growth factor receptor","explanation":"","oneSentence":"","technicalDetail":"CARBAMIDE's mechanism of action is not well-documented, but it is believed to involve the modulation of a specific protein or enzyme, potentially through competitive inhibition or allosteric binding."},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=%28CARBAMIDE%C2%AE%29","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=(CARBAMIDE®)","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T09:13:40.861382","_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T05:53:06.591258+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[],"genericName":"(carbamide®)","indications":{"approved":[{"name":"Metastatic non-small cell lung cancer","diseaseId":"metastatic-non-small-cell-lung-cancer","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05139017","phase":"PHASE2,PHASE3","title":"A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-01-14","conditions":["DLBCL","Diffuse Large B-Cell Lymphoma"],"enrollment":290,"completionDate":"2027-09-24"},{"nctId":"NCT03844061","phase":"PHASE2","title":"Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis","status":"RECRUITING","sponsor":"Hospital for Special Surgery, New York","startDate":"2019-07-29","conditions":["Systemic Sclerosis"],"enrollment":30,"completionDate":"2026-06-30"},{"nctId":"NCT06717347","phase":"PHASE3","title":"A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-01-27","conditions":["Diffuse Large B-Cell Lymphoma"],"enrollment":1046,"completionDate":"2032-03-29"},{"nctId":"NCT02298348","phase":"PHASE1","title":"Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"New Approaches to Neuroblastoma Therapy Consortium","startDate":"2015-10-08","conditions":["Neuroblastoma"],"enrollment":18,"completionDate":"2026-12"},{"nctId":"NCT07488988","phase":"PHASE2","title":"SCARFREE-001: Verteporfin for Scar Prevention","status":"NOT_YET_RECRUITING","sponsor":"Odense University Hospital","startDate":"2026-06","conditions":["Surgical Scar"],"enrollment":12,"completionDate":"2028-02"},{"nctId":"NCT06890884","phase":"PHASE2","title":"A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-04-11","conditions":["Lymphoma, Large B-Cell, Diffuse"],"enrollment":594,"completionDate":"2032-12-16"},{"nctId":"NCT06309485","phase":"PHASE2","title":"Phase 2 Study of WGI-0301 for Advanced HCC","status":"RECRUITING","sponsor":"Zhejiang Haichang Biotech Co., Ltd.","startDate":"2024-07-31","conditions":["Advanced Hepatocellular Carcinoma (HCC)"],"enrollment":60,"completionDate":"2027-03"},{"nctId":"NCT05624554","phase":"PHASE3","title":"A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-03-16","conditions":["Chronic Lymphocytic Leukemia","Small Lymphocytic Lymphoma"],"enrollment":300,"completionDate":"2031-03-17"},{"nctId":"NCT07010302","phase":"PHASE4","title":"Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSD","status":"NOT_YET_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2026-05","conditions":["NMOSD"],"enrollment":540,"completionDate":"2030-05"},{"nctId":"NCT05468359","phase":"PHASE1,PHASE2","title":"Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2022-11-07","conditions":["Refractory Solid Tumor","Hepatocellular Carcinoma","Malignant Solid Tumor","Pediatric Cancer","Pediatric Solid Tumor","Fibrolamellar Carcinoma"],"enrollment":64,"completionDate":"2037-06"},{"nctId":"NCT06738368","phase":"PHASE2","title":"Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"University of Washington","startDate":"2026-04-01","conditions":["B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative","T Acute Lymphoblastic Leukemia"],"enrollment":30,"completionDate":"2028-07-30"},{"nctId":"NCT06923111","phase":"","title":"PASS of Xromi Comparing Safety and Effectiveness in Children Under 2 Years With Sickle Cell Disease [PRECISE PASS]","status":"RECRUITING","sponsor":"Nova Laboratories Limited","startDate":"2025-06-09","conditions":["Sickle Cell Disease"],"enrollment":180,"completionDate":"2029-06"},{"nctId":"NCT04623541","phase":"PHASE1,PHASE2","title":"Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2020-11-25","conditions":["Relapsed/Refractory Chronic Lymphocytic Leukemia","Small Lymphocytic Lymphoma","Richter's Syndrome","Treatment-naïve High Risk Chronic Lymphocytic Leukemia"],"enrollment":195,"completionDate":"2028-02"},{"nctId":"NCT04663347","phase":"PHASE1,PHASE2","title":"Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2020-11-03","conditions":["Diffuse Large B-Cell Lymphoma","Follicular Lymphoma"],"enrollment":543,"completionDate":"2027-09-30"},{"nctId":"NCT04542824","phase":"PHASE1,PHASE2","title":"Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2020-08-20","conditions":["Diffuse Large B Cell Lymphoma","High-grade B-cell Lymphoma","Primary Mediastinal Large B Cell Lymphoma","Follicular Lymphoma","Marginal Zone Lymphoma","Small Lymphocytic Lymphoma"],"enrollment":78,"completionDate":"2027-09"},{"nctId":"NCT05605899","phase":"PHASE3","title":"Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Kite, A Gilead Company","startDate":"2023-02-10","conditions":["High-risk Large B-cell Lymphoma (LBCL)"],"enrollment":300,"completionDate":"2031-03"},{"nctId":"NCT02185560","phase":"","title":"Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With Sorafenib","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2014-06-27","conditions":["Thyroid Carcinoma"],"enrollment":453,"completionDate":"2026-09-30"},{"nctId":"NCT05495464","phase":"EARLY_PHASE1","title":"A Pilot \"Window-3\" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-11-18","conditions":["Lymphoma","Mantle Cell Lymphoma"],"enrollment":22,"completionDate":"2027-03-31"},{"nctId":"NCT07224035","phase":"PHASE4","title":"Helicobacter Pylori Screening and Treatment in the At-risk South Florida Community- AIM 1","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Miami","startDate":"2022-10-15","conditions":["H Pylori Infection","H Pylori Gastritis","Gastric Cancer"],"enrollment":500,"completionDate":"2027-11-06"},{"nctId":"NCT07224048","phase":"PHASE4","title":"Helicobacter Pylori Screening and Treatment in the At-risk South Florida Community-AIM 2","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Miami","startDate":"2024-11-06","conditions":["H. Pylori Infection","Gastric Cancer","Gastritis H Pylori"],"enrollment":75,"completionDate":"2027-11-06"},{"nctId":"NCT02158091","phase":"PHASE1,PHASE2","title":"A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2014-06-27","conditions":["Chronic Lymphocytic Leukemia"],"enrollment":32,"completionDate":"2026-07"},{"nctId":"NCT06094920","phase":"PHASE4","title":"Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2024-07-29","conditions":["Diabetes Mellitus Type 2 With Proteinuria","Diabetes Mellitus, Type 2","Diabetes Mellitus","Diabetes","Diabetes Complications","Albuminuria","Chronic Kidney Diseases","Chronic Kidney Disease Due to Type 2 Diabetes Mellitus","Chronic Kidney Disease stage3","Chronic Kidney Disease stage4","CKD","CKD Stage 3","CKD Stage 4"],"enrollment":12,"completionDate":"2025-09-24"},{"nctId":"NCT03949855","phase":"PHASE2","title":"Belimumab With Rituximab for Primary Membranous Nephropathy","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-03-06","conditions":["Membranous Nephropathy","Nephrotic Syndrome"],"enrollment":58,"completionDate":"2030-03-01"},{"nctId":"NCT02143726","phase":"PHASE2","title":"Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2014-10-09","conditions":["Refractory Hurthle Cell Thyroid Cancer"],"enrollment":35,"completionDate":"2028-08-06"},{"nctId":"NCT00989469","phase":"PHASE1,PHASE2","title":"Sorafenib With Irinotecan in Metastatic Colorectal Cancer (mCRC) and K-RAS Mutation","status":"COMPLETED","sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","startDate":"2009-02","conditions":["Metastatic Colorectal Cancer"],"enrollment":64,"completionDate":"2012-02"},{"nctId":"NCT04743661","phase":"PHASE2","title":"131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pediatric Brain Tumor Consortium","startDate":"2022-04-04","conditions":["Recurrent Medulloblastoma","Recurrent Ependymoma"],"enrollment":62,"completionDate":"2027-09-30"},{"nctId":"NCT06091865","phase":"PHASE3","title":"A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2023-12-13","conditions":["Diffuse Large B-cell Lymphoma (DLBCL)"],"enrollment":904,"completionDate":"2029-09-02"},{"nctId":"NCT03164057","phase":"PHASE2","title":"A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2017-06-15","conditions":["Acute Myeloid Leukemia","Myelodysplastic Syndromes"],"enrollment":206,"completionDate":"2027-06"},{"nctId":"NCT00826540","phase":"PHASE2","title":"Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2009-09","conditions":["Recurrent Colon Cancer","Recurrent Rectal Cancer","Stage IV Colon Cancer","Stage IV Rectal Cancer"],"enrollment":83,"completionDate":"2014-02"},{"nctId":"NCT03500731","phase":"PHASE1,PHASE2","title":"Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure","status":"RECRUITING","sponsor":"Paul Szabolcs","startDate":"2018-04-19","conditions":["Idiopathic Pulmonary Fibrosis","Emphysema or COPD"],"enrollment":8,"completionDate":"2028-12"},{"nctId":"NCT04047628","phase":"PHASE3","title":"Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-12-19","conditions":["Relapsing Multiple Sclerosis","Relapsing Remitting Multiple Sclerosis","Secondary Progressive Multiple Sclerosis"],"enrollment":156,"completionDate":"2029-10"},{"nctId":"NCT05468320","phase":"PHASE3","title":"Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura","status":"COMPLETED","sponsor":"Sanofi","startDate":"2022-11-21","conditions":["Thrombotic Thrombocytopenic Purpura"],"enrollment":51,"completionDate":"2024-12-26"},{"nctId":"NCT05952024","phase":"PHASE2","title":"Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-07-16","conditions":["Diffuse Large B-Cell Lymphoma"],"enrollment":80,"completionDate":"2027-08-24"},{"nctId":"NCT06015750","phase":"PHASE4","title":"Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia","status":"WITHDRAWN","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2026-07-29","conditions":["Hypophosphatasia"],"enrollment":0,"completionDate":"2030-03-13"},{"nctId":"NCT01871766","phase":"PHASE2","title":"Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2013-12-04","conditions":["Rhabdomyosarcoma"],"enrollment":115,"completionDate":"2030-06"},{"nctId":"NCT03755791","phase":"PHASE3","title":"Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Exelixis","startDate":"2018-06-10","conditions":["Hepatocellular Carcinoma"],"enrollment":837,"completionDate":"2026-07-31"},{"nctId":"NCT01046825","phase":"PHASE2,PHASE3","title":"Mature B-Cell Lymphoma And Leukemia Study III","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2010-09-09","conditions":["Mature B-Cell Lymphoma"],"enrollment":128,"completionDate":"2027-08"},{"nctId":"NCT07272122","phase":"PHASE3","title":"Reducing Filth Fly Populations and Transmission of Diarrhoeal Pathogens in Harsh Settings","status":"NOT_YET_RECRUITING","sponsor":"The Mentor Initiative","startDate":"2025-12-10","conditions":["Diarrheal Diseases"],"enrollment":5676,"completionDate":"2027-12-19"},{"nctId":"NCT06626516","phase":"PHASE1,PHASE2","title":"Tebentafusp-tebn With LDT in Metastatic UM","status":"RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2025-10-15","conditions":["Metastatic Uveal Melanoma"],"enrollment":109,"completionDate":"2032-08"},{"nctId":"NCT05687500","phase":"PHASE2","title":"Oral Glibenclamide in Preterm Infants With Hyperglycaemia (GALOP)","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-05-20","conditions":["Transient; Hypoglycemia, Neonatal","Preterm","Glibenclamide Adverse Reaction"],"enrollment":35,"completionDate":"2027-02-20"},{"nctId":"NCT05464680","phase":"NA","title":"Pulmonary Diffusion of Antibiotics in Patients Admitted for ARDS Following SARS-CoV-2 Pneumonia","status":"COMPLETED","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2022-11-24","conditions":["ARDS","SARS-CoV 2 Pneumonia"],"enrollment":34,"completionDate":"2025-05-09"},{"nctId":"NCT06944275","phase":"","title":"Characterising the Loss of Haemostasis in Haemorrhagic Fever With Renal Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Liverpool School of Tropical Medicine","startDate":"2026-05-01","conditions":["Haemorrhagic Fever With Renal Syndrome"],"enrollment":62,"completionDate":"2027-08-31"},{"nctId":"NCT05400122","phase":"PHASE1","title":"Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer","status":"SUSPENDED","sponsor":"David Wald","startDate":"2022-09-09","conditions":["Colorectal Cancer","Hematologic Malignancy","Rectum Cancer","Acute Myeloid Leukemia","Myelodysplastic Syndromes","Acute Lymphoblastic Leukemia","Chronic Myeloid Leukemia","Chronic Lymphocytic Leukemia","Hodgkin Lymphoma","Non Hodgkin Lymphoma","Myeloproliferative Syndrome","Plasma Cell Myeloma","Gastric Cancer","Esophageal Cancer","Esophagus Cancer","Gastric Cancer, Metastatic","Unresectable Esophageal Cancer","Metastatic Esophageal Cancer"],"enrollment":12,"completionDate":"2026-06-01"},{"nctId":"NCT02251548","phase":"PHASE2","title":"A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2014-10","conditions":["Chronic Lymphocytic Leukemia","Leukemia"],"enrollment":85,"completionDate":"2027-01"},{"nctId":"NCT05033522","phase":"PHASE2,PHASE3","title":"Immunotherapy for Advanced Liver Cancer","status":"SUSPENDED","sponsor":"Mirror Biologics, Inc.","startDate":"2023-08-01","conditions":["Hepatocellular Carcinoma"],"enrollment":150,"completionDate":"2026-12-01"},{"nctId":"NCT05371093","phase":"PHASE3","title":"Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kite, A Gilead Company","startDate":"2022-09-22","conditions":["Relapsed/Refractory Follicular Lymphoma"],"enrollment":231,"completionDate":"2030-10"},{"nctId":"NCT01908777","phase":"PHASE2","title":"A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2013-07-16","conditions":["T Cell Non-Hodgkin Lymphoma"],"enrollment":47,"completionDate":"2025-10-03"},{"nctId":"NCT05645718","phase":"PHASE2","title":"Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-07-14","conditions":["Leukemia"],"enrollment":27,"completionDate":"2029-12-31"},{"nctId":"NCT07049172","phase":"NA","title":"Rituximab and Targeted Nursing for Pediatric Nephrotic Syndrome","status":"COMPLETED","sponsor":"Wuhan Children's Hospital","startDate":"2021-01-01","conditions":["Nephrotic Syndrome in Children"],"enrollment":91,"completionDate":"2023-12-31"},{"nctId":"NCT04833114","phase":"PHASE3","title":"Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"GWT-TUD GmbH","startDate":"2021-04-30","conditions":["Relapsed Diffuse Large B-cell Lymphoma","Refractory Diffuse Large B-Cell Lymphoma"],"enrollment":306,"completionDate":"2025-12-31"},{"nctId":"NCT06326190","phase":"PHASE2","title":"177Lu-DOTATATE for Recurrent Meningioma","status":"RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2025-03-10","conditions":["Recurrent Meningioma"],"enrollment":136,"completionDate":"2028-12-22"},{"nctId":"NCT01810588","phase":"PHASE2","title":"Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2012-10-16","conditions":["Hematologic Malignancies"],"enrollment":270,"completionDate":"2028-04"},{"nctId":"NCT06197685","phase":"NA","title":"A Novel Combinatory Approach to Maximize Functional Recovery of Learning and Memory in Multiple Sclerosis","status":"RECRUITING","sponsor":"Kessler Foundation","startDate":"2024-02-12","conditions":["Multiple Sclerosis"],"enrollment":78,"completionDate":"2026-06-30"},{"nctId":"NCT07131410","phase":"NA","title":"Efficacy of Hyaluronic Acid Cream in Preventing Foot Ulceration Risk in Patients With Type 2 Diabetes and Moderate-to-Severe Peripheral Neuropathy: A Randomized Clinical Trial.","status":"ENROLLING_BY_INVITATION","sponsor":"University of Malaga","startDate":"2024-02-15","conditions":["DIABETES"],"enrollment":83,"completionDate":"2027-03-15"},{"nctId":"NCT05583071","phase":"PHASE2","title":"Methotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSL","status":"RECRUITING","sponsor":"University of Cologne","startDate":"2024-08-23","conditions":["Non-Hodgkin Lymphoma"],"enrollment":20,"completionDate":"2027-04"},{"nctId":"NCT03653338","phase":"PHASE1,PHASE2","title":"T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias","status":"RECRUITING","sponsor":"Paul Szabolcs","startDate":"2018-08-02","conditions":["Sickle Cell Anemia","Beta-thalassemia Major","Diamond-blackfan Anemia"],"enrollment":5,"completionDate":"2027-08-01"},{"nctId":"NCT02790515","phase":"PHASE2","title":"Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2016-07-14","conditions":["Acute Lymphoblastic Leukemia (ALL)","Acute Myeloid Leukemia (AML)","Myeloid Sarcoma","Chronic Myeloid Leukemia (CML)","Juvenile Myelomonocytic Leukemia (JMML)","Myelodysplastic Syndrome (MDS)","Non-Hodgkin Lymphoma (NHL)"],"enrollment":170,"completionDate":"2026-07-01"},{"nctId":"NCT04728633","phase":"PHASE2","title":"Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2021-09-27","conditions":["Metastatic Malignant Neoplasm in the Liver","Metastatic Uveal Melanoma","Stage IV Choroidal and Ciliary Body Melanoma AJCC V8"],"enrollment":28,"completionDate":"2027-06-30"},{"nctId":"NCT06474663","phase":"PHASE1","title":"A Phase I Study Investigating the Combination of Cladribine, Low Dose Cytarabine and Sorafenib Alternating With Decitabine in Pediatric Relapsed and Refractory Acute Leukemias","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-07-31","conditions":["Refractory Acute Leukemia","Relapsed Acute Leukemia"],"enrollment":0,"completionDate":"2025-07-31"},{"nctId":"NCT04688788","phase":"PHASE3","title":"Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2021-04-28","conditions":["Relapsing Remitting Multiple Sclerosis","Secondary Progressive Multiple Sclerosis","Primary Progressive Multiple Sclerosis"],"enrollment":600,"completionDate":"2029-05-05"},{"nctId":"NCT02561247","phase":"NA","title":"Prismaflex HF20 Set and Prismaflex® System 7.10/7.20 for Acute Continuous Renal Replacement Therapy (CRRT) in Children","status":"TERMINATED","sponsor":"Vantive Health LLC","startDate":"2015-11-10","conditions":["Acute Kidney Injury in Pediatric Patients"],"enrollment":23,"completionDate":"2018-04-06"},{"nctId":"NCT04578639","phase":"PHASE3","title":"Ocrelizumab VErsus Rituximab Off-Label at the Onset of Relapsing MS Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Haukeland University Hospital","startDate":"2020-11-02","conditions":["Relapsing Remitting Multiple Sclerosis"],"enrollment":214,"completionDate":"2025-09-14"},{"nctId":"NCT05024864","phase":"NA","title":"HELicobacter Pylori Screening to Prevent Gastrointestinal Bleeding in Patients With Acute Myocardial Infarction","status":"ACTIVE_NOT_RECRUITING","sponsor":"Karolinska Institutet","startDate":"2021-11-17","conditions":["Myocardial Infarction","Helicobacter Pylori Infection","GastroIntestinal Bleeding","Cardiovascular Diseases"],"enrollment":20000,"completionDate":"2030-01-17"},{"nctId":"NCT02953509","phase":"PHASE1,PHASE2","title":"Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2016-11-21","conditions":["Non Hodgkin Lymphoma"],"enrollment":178,"completionDate":"2024-03-25"},{"nctId":"NCT06986382","phase":"PHASE1,PHASE2","title":"Phase 1b/2a Trial of Allogeneic HSCT From an HLA-partially Matched Related or Unrelated Donor After TCRab+ T-cell/CD19+ B-cell Depletion for Patients With Monogenic and/or Early-onset Medically Refractory Crohn Disease","status":"NOT_YET_RECRUITING","sponsor":"Stanford University","startDate":"2025-07","conditions":["Crohn Disease"],"enrollment":14,"completionDate":"2040-07"},{"nctId":"NCT01350232","phase":"NA","title":"Treatment of Sickle Cell Anemia With Stem Cell Transplant","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2009-09","conditions":["Sickle Cell Anemia","Sickle Cell-hemoglobin C Disease","Sickle Cell-β0-thalassemia"],"enrollment":2,"completionDate":"2011-08"},{"nctId":"NCT03806452","phase":"PHASE2","title":"SIKAMIC (SIklos on Kidney Function and AlbuMInuria Clinical Trial)","status":"COMPLETED","sponsor":"Theravia","startDate":"2019-05-28","conditions":["Sickle Cell Disease"],"enrollment":86,"completionDate":"2024-05-30"},{"nctId":"NCT03623373","phase":"PHASE2","title":"Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2018-11-29","conditions":["Mantle Cell Lymphoma"],"enrollment":13,"completionDate":"2025-04-14"},{"nctId":"NCT04762069","phase":"PHASE2","title":"A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme","status":"ACTIVE_NOT_RECRUITING","sponsor":"CNS Pharmaceuticals, Inc.","startDate":"2021-05-18","conditions":["Glioblastoma Multiforme, Adult"],"enrollment":210,"completionDate":"2026-03-31"},{"nctId":"NCT02952144","phase":"NA","title":"Post Approval Study of Lixelle for the Treament of Dialysis-Related Amyloidosis","status":"RECRUITING","sponsor":"Kaneka Medical America LLC","startDate":"2015-10","conditions":["Dialysis Amyloidosis"],"enrollment":40,"completionDate":"2026-12"},{"nctId":"NCT03263559","phase":"PHASE2","title":"Haploidentical Bone Marrow Transplantation in Sickle Cell Patients (BMTCTN1507)","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2017-10-03","conditions":["Sickle Cell Disease"],"enrollment":95,"completionDate":"2025-01-29"},{"nctId":"NCT01415752","phase":"PHASE2","title":"Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eastern Cooperative Oncology Group","startDate":"2012-08-09","conditions":["Lymphoma","Mantle Cell Lymphoma"],"enrollment":373,"completionDate":"2031-09"},{"nctId":"NCT06887179","phase":"NA","title":"Point-of-Care Ultrasound in Chronic Heart Failure","status":"NOT_YET_RECRUITING","sponsor":"Masaryk University","startDate":"2025-04-01","conditions":["Cardiovascular Diseases"],"enrollment":112,"completionDate":"2029-12-31"},{"nctId":"NCT03899428","phase":"PHASE2","title":"Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC","status":"RECRUITING","sponsor":"Humanity & Health Medical Group Limited","startDate":"2019-05-02","conditions":["Hepatocellular Carcinoma"],"enrollment":30,"completionDate":"2025-12-31"},{"nctId":"NCT06797427","phase":"EARLY_PHASE1","title":"A Study to Assess the Pharmacokinetics of Sorafenib in Mesoporous Magnesium Carbonate (DPH001) Compared to Nexavar® (sorafenib) in Healthy Volunteers","status":"COMPLETED","sponsor":"Disruptive Pharma","startDate":"2025-02-10","conditions":["Healthy"],"enrollment":12,"completionDate":"2025-03-10"},{"nctId":"NCT05850546","phase":"PHASE3","title":"Rituximab in the First Episode of Paediatric Nephrotic Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Children's Hospital of Fudan University","startDate":"2025-03-01","conditions":["Steroid-Sensitive Nephrotic Syndrome"],"enrollment":138,"completionDate":"2026-12-28"},{"nctId":"NCT04986917","phase":"NA","title":"Laparoscopic Ventral Hernia Repair with Routine Defect Closure Using Su2ura® Approximation Device","status":"COMPLETED","sponsor":"Anchora Medical","startDate":"2022-01-19","conditions":["Ventral Hernia"],"enrollment":18,"completionDate":"2024-11-21"},{"nctId":"NCT06200779","phase":"PHASE4","title":"Tailored Vs. Empirical Helicobacter Pylori Infection Treatment","status":"NOT_YET_RECRUITING","sponsor":"Manuel Coelho da Rocha","startDate":"2025-09","conditions":["Helicobacter Pylori Infection"],"enrollment":160,"completionDate":"2026-12"},{"nctId":"NCT05586737","phase":"PHASE2","title":"Immunomodulatory Therapy in Women With Autoimmune Premature Ovarian Insufficiency","status":"COMPLETED","sponsor":"Angelica Lindén Hirschberg","startDate":"2019-04-29","conditions":["Autoimmune Diseases","Premature Ovarian Insufficiency"],"enrollment":15,"completionDate":"2024-12-15"},{"nctId":"NCT05221645","phase":"PHASE2","title":"Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Southampton","startDate":"2022-06-27","conditions":["Diffuse Large B Cell Lymphoma"],"enrollment":65,"completionDate":"2026-12-31"},{"nctId":"NCT02406092","phase":"PHASE3","title":"Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-10-13","conditions":["Non-Hodgkin Lymphoma"],"enrollment":139,"completionDate":"2021-06-30"},{"nctId":"NCT04116502","phase":"PHASE3","title":"MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera","status":"RECRUITING","sponsor":"University of Birmingham","startDate":"2019-10-25","conditions":["Polycythemia Vera"],"enrollment":586,"completionDate":"2030-04-01"},{"nctId":"NCT02950155","phase":"PHASE3","title":"A Study Evaluating the Safety and Efficacy of Rituximab in Patients With Myasthenia Gravis","status":"COMPLETED","sponsor":"Fredrik Piehl","startDate":"2016-10-16","conditions":["Generalized Myasthenia Gravis"],"enrollment":47,"completionDate":"2022-01-31"},{"nctId":"NCT06638138","phase":"NA","title":"Study of Artelon FLEXBAND® for Patients Undergoing Soft Tissue Reconstruction of the Anterior Talofibular Ligament (ATFL) to Treat Lateral Ankle Instability","status":"ENROLLING_BY_INVITATION","sponsor":"Stryker Trauma and Extremities","startDate":"2023-08-22","conditions":["Lateral Ankle Instability"],"enrollment":92,"completionDate":"2027-06-23"},{"nctId":"NCT05406401","phase":"PHASE2","title":"A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-07-14","conditions":["Lymphoma, Large B-Cell, Diffuse (DLBCL)"],"enrollment":60,"completionDate":"2029-04-26"},{"nctId":"NCT06175338","phase":"PHASE1","title":"Study, Evaluating Pharmacokinetics, Pharmacodynamics, Immunogenicity and Safety Profiles of Rituximab Compared to MabThera® in Patients With Rheumatoid Arthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mabscale, LLC","startDate":"2023-06-14","conditions":["Rheumatoid Arthritis"],"enrollment":208,"completionDate":"2025-04"},{"nctId":"NCT06586073","phase":"","title":"Topical Cosmetic Products for Hand and Foot Syndrome","status":"COMPLETED","sponsor":"Dermophisiologique s.r.l","startDate":"2022-08-31","conditions":["Hand Foot Skin Syndrome"],"enrollment":53,"completionDate":"2023-11-30"},{"nctId":"NCT01906216","phase":"PHASE3","title":"Sorafenib Chemoembolization Evaluation Controlled Trial","status":"COMPLETED","sponsor":"Air Force Military Medical University, China","startDate":"2013-09","conditions":["Hepatocellular Carcinoma"],"enrollment":199,"completionDate":"2022-06-30"},{"nctId":"NCT04707235","phase":"","title":"ESCORT-HU Extension: European Sickle Cell Disease Cohort - Hydroxyurea - Extension Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Theravia","startDate":"2020-08-21","conditions":["Sickle Cell Disease"],"enrollment":2093,"completionDate":"2025-08-21"},{"nctId":"NCT02157181","phase":"PHASE2","title":"Treatment of Hairy Cell Leukaemia Variant and Relapsing Hairy Cell Leukaemia With Cladribine Plus Rituximab","status":"COMPLETED","sponsor":"Jurgen Barth","startDate":"2004-06","conditions":["Hairy Cell Leukemia (HCL)"],"enrollment":89,"completionDate":"2013-01"},{"nctId":"NCT05804123","phase":"NA","title":"LiveSpo Navax® Supports the Treatment of Acute Rhinosinusitis and Otitis Media","status":"COMPLETED","sponsor":"Anabio R&D","startDate":"2021-10-28","conditions":["Upper Respiratory Tract Infections"],"enrollment":175,"completionDate":"2024-08-01"},{"nctId":"NCT00835991","phase":"PHASE1","title":"Glyburide/Metformin 5 mg/500 mg Film-Coated Tablets, Fed","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2003-02","conditions":["Healthy"],"enrollment":60,"completionDate":"2003-02"},{"nctId":"NCT00836472","phase":"PHASE1","title":"Glyburide/Metformin 5 mg/500 mg Film-Coated Tablets, Fasting","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2003-04","conditions":["Healthy"],"enrollment":60,"completionDate":"2003-04"},{"nctId":"NCT01199575","phase":"PHASE2","title":"Phase II Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2010-08","conditions":["Chronic Lymphocytic Leukemia","CLL"],"enrollment":30,"completionDate":"2022-07-19"},{"nctId":"NCT00551200","phase":"PHASE2","title":"Dose-Escalation Safety Study of HPN-100 to Treat Urea Cycle Disorders","status":"COMPLETED","sponsor":"Amgen","startDate":"2007-10","conditions":["Urea Cycle Disorders"],"enrollment":14,"completionDate":"2008-12"},{"nctId":"NCT05890690","phase":"NA","title":"Plasma Copeptin in Response to Oral Urea in Healthy Adults and Patients With Polyuria-polydipsia Syndrome","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2023-06-02","conditions":["Arginine Vasopressin Deficiency","Primary Polydipsia"],"enrollment":48,"completionDate":"2024-06-24"},{"nctId":"NCT02246218","phase":"PHASE4","title":"A Study of the Safety, Efficacy and Pharmacokinetics of Glycerol Phenylbutyrate in Pediatric Subjects Under 2 Years of Age With Urea Cycle Disorders","status":"COMPLETED","sponsor":"Amgen","startDate":"2014-12-31","conditions":["Urea Cycle Disorder"],"enrollment":27,"completionDate":"2017-07-17"},{"nctId":"NCT03934814","phase":"PHASE1","title":"Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and Lymphoma","status":"COMPLETED","sponsor":"I-Mab Biopharma US Limited","startDate":"2019-04-16","conditions":["Solid Tumor","Lymphoma"],"enrollment":98,"completionDate":"2023-01-10"},{"nctId":"NCT03335488","phase":"PHASE4","title":"Study of Glycerol Phenylbutyrate & Sodium Phenylbutyrate in Phenylbutyrate Naïve Patients With Urea Cycle Disorders (UCDs)","status":"COMPLETED","sponsor":"Amgen","startDate":"2018-02-20","conditions":["Urea Cycle Disorder"],"enrollment":16,"completionDate":"2022-12-20"},{"nctId":"NCT01796171","phase":"PHASE1,PHASE2","title":"A Phase 1/2 Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Nordic Nanovector","startDate":"2012-12","conditions":["Non-Hodgkin Lymphoma","Follicular Lymphoma"],"enrollment":191,"completionDate":"2022-10-27"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"chemblId":"CHEMBL383698"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"present","companyName":"German University in Cairo","relationship":"Current Owner"}],"publicationCount":1628,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"(CARBAMIDE®)","companyName":"German University in Cairo","companyId":"german-university-in-cairo","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T05:53:06.591258+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}